Moderna, Inc.לונג
MRNA- a vaccine biotechnology stock LONG
MRNA focuses on vaccine research and development and we are in the flu season an COVID is
lurking in the shadows and trying to make a comback. It had an excellent earnings report and
forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored
VWAP and is at the level of the first upper VWAP while in side the high volume area of the
volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing
position here and again the next time I see a dip on the 15-30-minute chart. I look forward
to take a piece out of the position after the next earnings report in about 75 days. I have an
alert for relative volume when the running mean is exceeded on the 30 minute chart which
notify me to take a look at the chart. This is illustrated on this longer time frame chart about
the days around earnings but occurs from time to time from other events. As an aside, if NVAX
gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be
the leading candidate to do a takeover, friendly or otherwise.
lurking in the shadows and trying to make a comback. It had an excellent earnings report and
forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored
VWAP and is at the level of the first upper VWAP while in side the high volume area of the
volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing
position here and again the next time I see a dip on the 15-30-minute chart. I look forward
to take a piece out of the position after the next earnings report in about 75 days. I have an
alert for relative volume when the running mean is exceeded on the 30 minute chart which
notify me to take a look at the chart. This is illustrated on this longer time frame chart about
the days around earnings but occurs from time to time from other events. As an aside, if NVAX
gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be
the leading candidate to do a takeover, friendly or otherwise.
כתב ויתור
המידע והפרסומים אינם אמורים להיות, ואינם מהווים, עצות פיננסיות, השקעות, מסחר או סוגים אחרים של עצות או המלצות שסופקו או מאושרים על ידי TradingView. קרא עוד בתנאים וההגבלות.